Share on StockTwits

Celldex Therapeutics (NASDAQ:CLDX) saw a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 15,195,178 shares, an increase of 15.1% from the April 30th total of 13,201,138 shares, reports. Currently, 17.0% of the company’s shares are short sold. Based on an average daily volume of 3,584,249 shares, the short-interest ratio is presently 4.2 days.

Several analysts have recently commented on the stock. Analysts at Ned Davis Research upgraded shares of Celldex Therapeutics from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. Separately, analysts at Jefferies Group raised their price target on shares of Celldex Therapeutics from $29.00 to $31.00 in a research note on Tuesday, March 4th. They now have a “buy” rating on the stock. Finally, analysts at Cantor Fitzgerald reiterated a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday, March 4th. They now have a $33.00 price target on the stock, down previously from $39.00. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $36.29.

Shares of Celldex Therapeutics (NASDAQ:CLDX) opened at 14.61 on Monday. Celldex Therapeutics has a 1-year low of $10.76 and a 1-year high of $38.84. The stock has a 50-day moving average of $13.97 and a 200-day moving average of $21.96. The company’s market cap is $1.306 billion.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.08. The company had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.34 million. During the same quarter in the previous year, the company posted ($0.23) earnings per share. The company’s revenue for the quarter was down 83.3% on a year-over-year basis. On average, analysts predict that Celldex Therapeutics will post $-1.32 earnings per share for the current fiscal year.

Celldex Therapeutics, Inc (NASDAQ:CLDX), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.